Related Experiment Videos
Current markers of myocardial ischemia and their validity in end-stage renal disease
1Renal Division, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
Insights
Diagnosing heart disease in end-stage renal disease patients is challenging. Troponin I is the most sensitive and specific marker for detecting cardiac ischemia in this population.
Area of Science:
- Cardiology
- Nephrology
- Biomarker Analysis
Background:
- Coronary artery disease (CAD) is a major cause of death in end-stage renal disease (ESRD) patients.
- Diagnosing myocardial disease in ESRD is difficult due to abnormal EKGs and atypical symptoms.
- Conventional cardiac injury markers lack specificity in ESRD patients.
Purpose of the Study:
- To evaluate the diagnostic utility of cardiac troponins for myocardial ischemia in ESRD patients.
- To identify the most reliable biomarker for detecting cardiac injury in this population.
Main Methods:
- Review of existing literature on cardiac biomarkers in ESRD.
- Comparison of the specificity and sensitivity of creatinine kinase-muscle brain enzyme, troponin T, and troponin I.
- Analysis of biomarker performance in the context of abnormal baseline EKGs and silent ischemia.
Main Results:
- Creatinine kinase-muscle brain enzyme shows nonspecific elevations in ESRD.
- Cardiac troponin T exhibits poor specificity in ESRD patients.
- Troponin I demonstrates high sensitivity and specificity for cardiac ischemia in ESRD.
Conclusions:
- Troponin I is the most sensitive and specific biomarker for diagnosing ischemic heart disease in patients with end-stage renal disease.
- Troponin I facilitates accurate risk stratification and bedside diagnosis in this high-risk group.
Abstract:
Coronary artery disease is highly prevalent in patients with end-stage renal disease, and accounts for much of their observed morbidity and mortality. Despite this, diagnosing myocardial disease in this population remains problematic, because many patients present with abnormal baseline electrocardiograms, frequently compounded by silent or atypical symptoms. Conventionally used enzymatic markers of cardiac injury have not resolved this dilemma because of their poor specificity in end-stage renal disease. In particular, nonspecific elevations in creatinine kinase-muscle brain enzyme, a widely accepted marker of cardiac injury, have been consistently observed in the absence of other demonstrable evidence for cardiac injury. Recently, the cardiac troponins (troponin I and troponin T) have emerged as more sensitive markers for cardiac ischemia, facilitating rapid bedside diagnosis and early risk stratification. Unfortunately, cardiac troponin T shows poor specificity in end-stage renal disease, possibly because of variable expression in extracardiac tissues. On the other hand, troponin I consistently maintains a high sensitivity and specificity, and is the most sensitive marker for ischemic heart disease in this patient population.